These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29344738)

  • 41. Results of contracture tests with halothane, caffeine, and ryanodine depend on different malignant hyperthermia-associated ryanodine receptor gene mutations.
    Fiege M; Wappler F; Weisshorn R; Ulrich Gerbershagen M; Steinfath M; Schulte Am Esch J
    Anesthesiology; 2002 Aug; 97(2):345-50. PubMed ID: 12151923
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A truncation in the RYR1 gene associated with central core lesions in skeletal muscle fibres.
    Rossi D; De Smet P; Lyfenko A; Galli L; Lorenzini S; Franci D; Petrioli F; Orrico A; Angelini C; Tegazzin V; Dirksen R; Sorrentino V
    J Med Genet; 2007 Feb; 44(2):e67. PubMed ID: 17293538
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Identical de novo mutation in the type 1 ryanodine receptor gene associated with fatal, stress-induced malignant hyperthermia in two unrelated families.
    Groom L; Muldoon SM; Tang ZZ; Brandom BW; Bayarsaikhan M; Bina S; Lee HS; Qiu X; Sambuughin N; Dirksen RT
    Anesthesiology; 2011 Nov; 115(5):938-45. PubMed ID: 21918424
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dietary Caffeine Synergizes Adverse Peripheral and Central Responses to Anesthesia in Malignant Hyperthermia Susceptible Mice.
    Aleman M; Zhang R; Feng W; Qi L; Lopez JR; Crowe C; Dong Y; Cherednichenko G; Pessah IN
    Mol Pharmacol; 2020 Oct; 98(4):351-363. PubMed ID: 32764093
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A multi-dimensional analysis of genotype-phenotype discordance in malignant hyperthermia susceptibility.
    Ibarra Moreno CA; Kraeva N; Zvaritch E; Figueroa L; Rios E; Biesecker L; Van Petegem F; Hopkins PM; Riazi S
    Br J Anaesth; 2020 Dec; 125(6):995-1001. PubMed ID: 32861507
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutational analysis of putative calcium binding motifs within the skeletal ryanodine receptor isoform, RyR1.
    Fessenden JD; Feng W; Pessah IN; Allen PD
    J Biol Chem; 2004 Dec; 279(51):53028-35. PubMed ID: 15469935
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic variation in RYR1 and malignant hyperthermia phenotypes.
    Carpenter D; Robinson RL; Quinnell RJ; Ringrose C; Hogg M; Casson F; Booms P; Iles DE; Halsall PJ; Steele DS; Shaw MA; Hopkins PM
    Br J Anaesth; 2009 Oct; 103(4):538-48. PubMed ID: 19648156
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Phenotyping malignant hyperthermia susceptibility by measuring halothane-induced changes in myoplasmic calcium concentration in cultured human skeletal muscle cells.
    Girard T; Treves S; Censier K; Mueller CR; Zorzato F; Urwyler A
    Br J Anaesth; 2002 Oct; 89(4):571-9. PubMed ID: 12393358
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reduced threshold for store overload-induced Ca
    Chen W; Koop A; Liu Y; Guo W; Wei J; Wang R; MacLennan DH; Dirksen RT; Chen SRW
    Biochem J; 2017 Aug; 474(16):2749-2761. PubMed ID: 28687594
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Functional Characterization of C-terminal Ryanodine Receptor 1 Variants Associated with Central Core Disease or Malignant Hyperthermia.
    Parker R; Schiemann AH; Langton E; Bulger T; Pollock N; Bjorksten A; Gillies R; Hutchinson D; Roxburgh R; Stowell KM
    J Neuromuscul Dis; 2017; 4(2):147-158. PubMed ID: 28527222
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 4-Chloro-m-cresol: a specific tool to distinguish between malignant hyperthermia-susceptible and normal muscle.
    Herrmann-Frank A; Richter M; Lehmann-Horn F
    Biochem Pharmacol; 1996 Jul; 52(1):149-55. PubMed ID: 8678899
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Strenuous exercise triggers a life-threatening response in mice susceptible to malignant hyperthermia.
    Michelucci A; Paolini C; Boncompagni S; Canato M; Reggiani C; Protasi F
    FASEB J; 2017 Aug; 31(8):3649-3662. PubMed ID: 28465322
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
    Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
    Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genotype-Phenotype Correlations of Malignant Hyperthermia and Central Core Disease Mutations in the Central Region of the RYR1 Channel.
    Murayama T; Kurebayashi N; Ogawa H; Yamazawa T; Oyamada H; Suzuki J; Kanemaru K; Oguchi K; Iino M; Sakurai T
    Hum Mutat; 2016 Nov; 37(11):1231-1241. PubMed ID: 27586648
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Functional characterization of ryanodine receptor (RYR1) sequence variants using a metabolic assay in immortalized B-lymphocytes.
    Zullo A; Klingler W; De Sarno C; Ferrara M; Fortunato G; Perrotta G; Gravino E; Di Noto R; Lehmann-Horn F; Melzer W; Salvatore F; Carsana A
    Hum Mutat; 2009 Apr; 30(4):E575-90. PubMed ID: 19191333
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Functional studies of RYR1 mutations in the skeletal muscle ryanodine receptor using human RYR1 complementary DNA.
    Sato K; Pollock N; Stowell KM
    Anesthesiology; 2010 Jun; 112(6):1350-4. PubMed ID: 20461000
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effects of dantrolene in the presence or absence of ryanodine receptor type 1 variants in individuals predisposed to malignant hyperthermia.
    Noda Y; Mukaida K; Miyoshi H; Nakamura R; Yasuda T; Saeki N; Nishino I; Tsutsumi YM
    Anaesth Intensive Care; 2022 Jul; 50(4):312-319. PubMed ID: 35549722
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Discordance between malignant hyperthermia susceptibility and RYR1 mutation C1840T in two Scandinavian MH families exhibiting this mutation.
    Fagerlund TH; Ording H; Bendixen D; Islander G; Ranklev Twetman E; Berg K
    Clin Genet; 1997 Dec; 52(6):416-21. PubMed ID: 9520251
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evidence for a spontaneous C1840-T mutation in the RYR1 gene after DNA fingerprinting in a malignant hyperthermia susceptible family.
    Steinfath M; Seranski P; Singh S; Fiege M; Wappler F; Schulte Am Esch J; Scholz J
    Naunyn Schmiedebergs Arch Pharmacol; 2002 Oct; 366(4):372-5. PubMed ID: 12237752
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.